Obesity leads to asthma via various mechanisms including inflammatory signalling and fibrotic changes; therefore, recent studies have revealed that anti-inflammatory or anti-fibrotic drugs including roflumilast, anti-IL-17 and anti-IL-1β antibodies could have significant effects on obesity-induced asthma without significant weight loss10,23,24. Here, IL17A is linked to asthma.